Propanc Biopharma stock analysis
Want to see PPCB full AI Analyst Report?
Propanc Biopharma (PPCB) Stock Price & Analysis
PPCB Stock Chart & Stats
- Day’s Range
- $1.91 - $1.98
- 52-Week Range
- $1.63 - $315.17
- Previous Close
- $1.92
- Volume
- N/A
- Average Volume (3M)
- 36.73K
- Market Cap
- $2.01M
- Enterprise Value
- $3.62M
- Total Cash (Recent Filing)
- $258.37K
- Total Debt (Recent Filing)
- $42.74K
- Price to Earnings (P/E)
- ―
- Beta
- -0.86
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low reported debt reduces fixed financial obligations and limits leverage-related pressure on the business. Positive equity also provides a remaining capital base, giving the company more flexibility than a similarly unprofitable developer with a highly indebted balance sheet.
Losses Narrowing
The substantial reduction in losses from FY2025 indicates that the company has moved away from its earlier peak level of expense or impairment burden. Although profitability remains deeply negative, lower losses could improve capital efficiency if the trend persists alongside clinical development.
Focused Oncology Pipeline
A defined focus on oncology gives Propanc a concentrated strategic direction rather than a broad, unfocused development portfolio. Its therapeutic candidates provide a clear basis for future value creation if research and development translate into clinical and regulatory progress.
Bears Say
No Revenue And Large Losses
The absence of reported revenue means the company has not yet demonstrated commercial traction or an operating model that can support itself. Persistent large losses limit earnings visibility and leave future financial performance dependent on successful development and eventual commercialization.
Persistent Cash Burn
Ongoing negative operating and free cash flow shows that Propanc is consuming cash to fund operations rather than generating internal financing. Continued burn can erode its capital base and increase the importance of future financing or other funding sources for development.
Nasdaq Delisting Risk
The listing deficiency creates a structural financing and market-access risk beyond ordinary share-price volatility. A future delisting could reduce trading liquidity, constrain public-market capital raising, and limit equity-based incentives, complicating the company’s ability to fund development.
Propanc Biopharma News
Propanc Biopharma targets February start for first-in-human cancer study
Propanc Biopharma (PPCB) announced it is advancing its clinical development program for PRP, its investigational proenzyme-based therapeutic candidate, as preparations continue for its planned Phase 1b, first-in-human study in up
Propanc Biopharma announces new preclinical research from PRP programs
Propanc Biopharma (PPCB) announced new preclinical research from an academic-industry collaboration from the Universities of Jaen and Granada, led by Maria Belen Toledo, has identified pancreatic proenzyme formulation, PRP, as
Propanc Biopharma issues comparative analysis of PRP versus ERAS-0015
Propanc Biopharma (PPCB) issued a comparative analysis of lead candidate PRP against recently reported clinical datasets from Erasca’s pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcinoma, PDAC. The analysis follows
PPCB FAQ
What was Propanc Biopharma’s price range in the past 12 months?
What is Propanc Biopharma’s market cap?
When is Propanc Biopharma’s upcoming earnings report date?
How were Propanc Biopharma’s earnings last quarter?
Is Propanc Biopharma overvalued?
Does Propanc Biopharma pay dividends?
What is Propanc Biopharma’s EPS estimate?
How many shares outstanding does Propanc Biopharma have?
What happened to Propanc Biopharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Propanc Biopharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Propanc Biopharma
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Nathanielsz
- Employees
- 2
- Website
- www.propanc.com
- Address
- 302, 6 Butler Street, Camberwell, VIC, 3124, AU
Propanc Biopharma (PPCB) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 4 | 0 | 8 |













